Transformation in the Pharmaceutical Industry—A Systematic Analysis of Operational Evidence

References

1. 1.↵
   1. Shafiei N.,
   2. Ford J. L.,
   3. Morecroft C. W.,
   4. Lisboa P. J.,
   5. Taylor M. J.

   Characterization of the evolution of the pharmaceutical regulatory environment. PDA J. Pharm. Sci. Technol. Accepted for publication in July/August 2013 edition.
2. 2.↵
   1. Shafiei N.,
   2. Ford J. L.,
   3. Morecroft C. W.,
   4. Lisboa P. J.,
   5. Taylor M. J.,
   6. Mouzughi Y.

   Transformation in the pharmaceutical industry—a systematic review of the literature. PDA J. Pharm. Sci. Technol. 2013; 67:105–122.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Wagner V.,
   2. Dullaart A.,
   3. Bock A. K.,
   4. Zweck A.

   The emerging nanomedicine landscape. Nature Biotechnol. 2006, 24 (10), 1211–1217.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Woodcock J.,
   2. Buckman S.,
   3. Goodsaid F.,
   4. Walton M. K.,
   5. Zineh I.

   Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert Opinion on Medical Diagnostics 2011, 5 (5), 369–374.

   OpenUrlPubMed
5. 5.↵
   1. Hamburg M. A.

   Effective Enforcement and Benefits to Public Health. Food and Drug Law Institute, FDA: Silver Spring, MD, August 6, 2009. http://www.fda.gov/NewsEvents/Speeches/ucm175983.htm. Accessed October 20, 2011.
6. 6.↵
   1. Shafiei N.,
   2. Ford J. L.,
   3. Morecroft C. W.,
   4. Lisboa P. J.,
   5. Taylor M. J.,
   6. Mouzughi Y.

   Transformation in the Pharmaceutical Industry: transformationinduced quality risks–a survey. PDA J Pharm Sci Technol May/June 2013 67:229–246.

   OpenUrlAbstract/FREE Full Text